Nearly every obesity drug trial produces more than one weight-loss number, and which one gets quoted in a headline, a press release, or a comparison chart can make a meaningful difference in how impressive a result looks. Understanding the distinction between them is one of the more useful research-literacy skills for reading coverage of GLP-1 and amylin drug trials.

Observed vs. Placebo-Adjusted Weight Loss

"Observed" weight loss is simply the average change in body weight for people taking the drug, full stop. "Placebo-adjusted" or "placebo-corrected" weight loss subtracts out the change seen in the trial's placebo group over the same period. That subtraction matters because placebo groups in obesity trials don't just sit still, they typically lose some weight too, often in the range of 2% to 3% of body weight, from the lifestyle counseling, dietary advice, and simple attention that come with trial participation regardless of which group someone is assigned to. A drug that produces 18% observed weight loss against a placebo group that lost 3% has a placebo-adjusted effect of roughly 15%, a real difference between the two framings.

Intention-to-Treat vs. Completers-Only

A second, often bigger source of confusion is whether a reported result includes everyone originally enrolled, the intention-to-treat (ITT) population, or only the people who stayed on the drug for the full study, sometimes called a completers or on-treatment analysis. Obesity and diabetes trials often see meaningful numbers of participants stop treatment early, frequently due to gastrointestinal side effects, and people who stop a drug early, on average, lose less weight than people who stay on it the whole time. A completers-only analysis excludes those early dropouts, which mechanically inflates the average result compared to an ITT analysis that counts everyone, including people who quit after a few weeks.

Why "Up To X%" Headlines Can Overstate the Typical Result

Trial results are often reported at multiple doses and multiple time points, and press coverage understandably gravitates toward the single biggest number available, typically the highest dose tested, at the latest time point measured, sometimes using an observed rather than placebo-adjusted figure, and occasionally a completers-only rather than ITT figure. None of that is necessarily dishonest; it's usually a real result from the trial. But stacking several of those choices together can produce a headline figure meaningfully larger than what an average patient, taking a typical dose and counted alongside everyone who started treatment, actually experienced.

How to Read These Numbers More Carefully

When comparing drugs or trials, it helps to check whether the percentages being compared use the same basis, placebo-adjusted versus observed, and ITT versus completers, since comparing a placebo-adjusted, ITT figure for one drug against an observed, completers-only figure for another can make two genuinely similar drugs look very different. Peer-reviewed trial publications typically report both the ITT and completers analyses, along with placebo-adjusted figures, in their full results tables, even when a press release or news summary highlights only the largest one.

The Bottom Line

None of this means headline trial percentages are fabricated or meaningless; they're real results from real trials. But the specific number that ends up in a headline is often the most favorable valid framing available, not necessarily the number that best predicts what an average patient should expect. Reading past the single percentage to check what it's actually measuring is one of the more practical ways to evaluate competing claims about weight-loss drugs.